Möchten Sie immer auf dem neuesten Stand bleiben?

Novartis takes action to strengthen portfolio and capital allocation, starts share buyback Blood transfusion diagnostics unit divested as part of ongoing portfolio management Reiterates optimal...

Spain-based Grifols to acquire Novartis blood transfusion diagnostics unit for USD 1.675 billion Divestiture further enhances Novartis focus on strategic businesses Basel, November 11, 2013 -...

Group net sales up 4% (+6% cc[1]) to USD 14.3 billion in third quarter and up 2% (+4% cc) in first nine months; all divisions contributed to growth Core operating income of USD 3.6 billion...

QVA149 (indacaterol/glycopyrronium) is the first once-daily fixed-dose combination of both a LABA and a LAMA bronchodilator to gain positive CHMP opinion Pivotal Phase III IGNITE data showed...

Basel, July 17, 2013 - The Novartis Board of Directors today announced a final agreement with its former Chairman, Dr. Daniel Vasella. Since the Novartis Annual General Meeting (AGM), Dr. Daniel...

Group net sales increased 1% (+3% cc[1]) versus year ago to USD 14.5 billion in second quarter, up 2% (+4% cc) to USD 28.5 billion in first half Core operating income was USD 3.8 billion (-2%,...

FIXTURE trial of more than 1,300 moderate-to-severe plaque psoriasis patients showed superiority of secukinumab (AIN457) to Enbrel® (etanercept) All primary and secondary endpoints were met ...

Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical need  If approved, RLX030 has the potential to be the first treatment...

Everolimus plus trastuzumab and vinorelbine met primary endpoint of extending PFS compared to placebo plus trastuzumab and vinorelbine after prior therapy[1] Results of Phase III trial, BOLERO-3,...

Dr. Joerg Reinhardt to receive total annual compensation of CHF 3.8 million through combination of cash and stock for serving as Chairman of Novartis. Dr. Reinhardt also to be compensated over the...